Figure 4: I wonder how robust the networks/findings are in this figure? What happens if you were to modify the |r|>.4 and p<0.05 thresholds? Would the findings be consistent? It would be good to perform a quick sensitivity analysis. Perhaps, use different values of r to see how it changes. Also, how many of the p-values would survive multiple testing. I understand that this is mostly visual and exploratory, but it would be good to understand how strong these interactions are. Perhaps this could be discussed to highlight the fact that many of those are likely false positives. Redundancy across assays: As shown on Figure 5 , it is clear that some of the assays/variables are highly correlated. I was wondering if the prediction accuracy presented in Figure 2 could be improved if one were to downselect the variables to reduce correlation. While the Elastic Net can deal with collinearity, its performance can be greatly affected by it. Also, scientifically speaking it would be great to come up with a minimal set of variables/assays that capture the breadth of antibody function while minimizing redundancy across variables. I understand that this is difficult to do based on a single dataset, but the authors might have some other data that could be used for that. I would at least discuss it. Figure 5 : As discussed above, this is an interesting figure/result. I would propose to use the mean squared error (MSE) for the y-axis as it is more standard for evaluating prediction accuracy. Related, for 5b, report r2 instead of r. Use of biological replicates in Figure 5 . I don't really understand why the correlation between biological replicates would be an upper bound. Are these technical or biological replicates? If biological, I would argue that the correlation should probably be lower as there might be substantial variability across subjects. I think this needs to be clarified.
Minor comments:
Figure 4: The legend in this figure should say |r|>0.4 and not r>|.4|. Code and data availability: Given the importance of the computational analyses performed, it would be great to share the data and code for full reproducibility.
We thank the reviewers for their thoughtful comments, questions, and suggestions. Responses to each point made in review are described below, and modifications made the manuscript have been tracked in the resubmission. We believe that the manuscript has been substantially improved based on addressing these comments, and we further note that the revised supplemental materials now includes raw data, code, and model outputs.
Reviewer #3:
Alter et al. applied their previously-described "systems serology" antibody biophysical property profiling approach to a large cohort of HIV-infected individuals. The resulting high-dimensional data was used to build models that differentiate between the humoral immune responses of elite controllers, viremic controllers, and treated and untreated disease progressors. The analysis yielded a number of intriguing differences between subject groups provide rich datasets for further analyses. The data/models did an impressive job in discriminating between study groups, as well as in predicting antibody effector functions.
A more thorough explanation of analyses and figures are needed in many areas. Many of the figures were not explained in adequate detail for scientists without systems biology/statistics expertise. For example, Figure 2B-D were not detailed outside of the figure legend (what are confusion matrices or LOD scores?).
In the revised manuscript we have taken care to better introduce terms associated with our analysis approach that may be unfamiliar to readers, as well as to discuss the figures in greater depth.
See for example, page 4-5: "Given the rich data collected, a machine learning approach was employed to identify combinations of a humoral response features able to predict subject class and antibody effector function. Cross-validated classifiers trained to distinguish subject groups identified minimal sets of antibody features that accurately and robustly discriminated among all four subject groups, between viremic and aviremic subjects, and between controllers and progressors (Fig.2) . Subject class was determined by a class score (LOD, or Log 2 Odds Ratio) that defined the relative likelihood of a given subject's assignment to one as compared to other classes. Differentiation across EC, VC, TP and UP groups was accomplished with approximately 60% accuracy, as compared to the approximately 25% accuracy expected at random based on class size for this 4-group differentiation model, and as observed when scrambled study data was used as a modeling input (Fig.2a) . Approximately 75% accuracy was observed for the 2-way classifications aimed at differentiation of subjects by progression (EC and VC versus TP and UP) or by viremia (EC and TP versus VC and UP), as compared to the approximately 50% accuracy expected by chance, or again, observed when study data was permuted prior to learning (Fig.2a) . Confusion matrices (Fig.2b-d) , which compare actual and predicted classifications, indicated that with the exception of UPs, who could not be confidently differentiated from TPs or VCs, most classes were predicted well. While there was little evidence of systematic confusion, among misclassified VCs and TPs, most were modeled to be UPs, consistent with the difficulty noted in classification of this group, and suggestive that they may have a less distinct humoral profile as a group. Further, class score can be considered a measure of model confidence (Fig.2b-d) . Whereas in the 2-way classifications misclassified subjects often had marginal class scores, in the 4-group differentiation models, incorrect predictions were often made confidently. For example, misclassified ECs tended to be confidently predicted as either TPs or VCs, suggestive of the existence of some subjects with profiles that are considerably more consistent with these classes."
The manuscript would also be improved by more clearly highlighting the predictive variables in the models, providing further biological interpretation, and bridging these with some of the main biological findings.
Based on this thoughtful suggestion we have expanded the manuscript text to more fully describe and interpret the features identified as predictive of group and functional activity.
See for example, page 6: "For example, numerous bisected glycoforms contributed to the differentiation of aviremic from viremic subjects when the glycosylation profiles of HIV envelope-specific antibodies were used to predict viral load status (Appendix Fig S3) , suggesting a difference in the level of antibody bisection between groups.… …Whether this glycosylation state difference associated with viral load may be a cause or effect of viremic status remains to be determined, but potential mechanistic relevance to antiviral humoral immunity is suggested by previous studies demonstrating that antibodies with bisected glycans exhibit enhanced FcγR3 recognition and ADCC activity (31), a mechanistic link that was further explored within this data set in models of antibody function. " We apologize for the lack of clarity regarding how the individual examples selected for inclusion in Figure 3 relate to functional and class models. The manuscript text and figure set has been significantly expanded to specifically highlight the featuers that are uniquely selected by the model and make the linkage more clear, as indicated by the example above, and in greater detail below. Figure S2 A number of issues are raised here, which have been addressed as follows:
I assume that the bottom panel of
 In the revised manuscript we have made more explicit reference to Appendix Figure S2 (which relates to the classification results presented in Figure 2b ). This figure had been poorly referenced as "Figs.S1,2" in the original submission.  We have ensured that groups are referred to consistently throughout the manuscript, figures, and Appendix (ie: replacing "nonviremic" with "aviremic").  We have provided detail on the basis for inclusion of the specific examples selected for Figure 3 and provided the "missing link" the reviewer is looking for in terms of relating these individual measures to the models as follows: o For Figure 3a : new text in the results and a new supplemental figure (Appendix Figure  S3 ) describing the use of glycan data to predict aviremic vs. viremic classes that raises the hypothesis that glycan bisection may differ among groups is included to provide the basis for investigating this parameter in the context of these groups. o For Figure 3b : an expanded description of the linkage between the model of subject class whose in response to the more direct reviewer comment on this matter below.  Given the basis for the plots in Figure 3 is now (better) provided, we have not addressed the multiple hypothesis testing concern raised as we hope it is now clear that these features were not selected on the basis of their p-values, but were investigated based on modeling results.  Beyond the literature supporting the biological relevance of a difference in antibody bisection, the importance of this difference to the sample set evaluated within this study is now supported by drawing attention to: o Figure 6d , which reports the contribution of IgG bisection to the model of ADCC activity (see also Appendix Figure S6 ), and the correlation of bisected glycoforms with ADCC activity (see also Appendix Figure S7 ). o Figure 6d , which also illustrates the predominance of FcgammaR3 ligation propensity assessments to contribute to ADCC activity models. Collectively, these relationships support both the relevance of bisection to ADCC activity, and viremic/aviremic group differentiation, within this study, and provide the basis for the inclusion of this feature in Figure 3 , and the justification for the description in the figure legend as an example of "differentiating humoral response features identified by classification".
Similarly, another interesting result is that ECs have elevated levels of p24 antibodies, which is readily apparent in the volcano plot. However, is this true in the classification model? I cannot tell, as the legend to Figure S2C (controller/progressor) is not legible.
The elevation of p24-specific antibodies among ECs evident in the volcano plot is indeed reflected in the models of subject class. In the 4 way classification models, of the 16 features with positive coefficient weights for the EC group, 9 represent p24/Gag-specific antibody measurements. In fact, 2 of the top 3 positive coefficients are p24/Gag-specific.
We apologize for the lack of label clarity. Though the supplemental pdfs supplied can generally be clearly read under magnification, we recognize that the small print required to fit the labels is a limitation to the utility of the supplemental graphs when printed. Given the difficulty in reading labels on supplemental figures at print size, and the potential interest in and utility of the data underlying these graphs, we have now included tables reporting the features and coefficient weights for models in the supplemental data.
Relevant to the question raised by the reviewer, we have used these tables to generate a list (Response to Review * * * * *** *** * * ** ** * * * * * ** * * *** * * * ** * * * * ** ** *** * *** ** ** * * * *** ** * * * ** *** * *** ** ** ** *** *** *** ** *** *** *** ** *** * ** *** ** ** ** * * ** ** *** ** ** *** *** * *** *** *** *** ** *** *** *** ** ** * * * * ** * *** *** *** *** *** *** *** * *** ** *** *** *** *** *** ** ** *** *** ** *** *** *** *** *** ** *** ** ** ** *** *** *** *** *** *** *** * *** * * * *** * *** ** *** *** *** * ** * *** ** *** *** *** *** *** *** *** * * *** * ** * * * * *** ** *** *** * ** *** *** ** ** *** ** *** ** * ** *** *** *** *** ** *** *** *** ** * * *** ** ** ** * ** *** * ** *** ** * ** *** * *** ** ** *** *** *** *** *** *** *** *** *** *** *** *** *** *** * * ** *** ** *** *** *** *** * *** * ** ** *** *** *** *** *** *** * *** *** *** *** *** ** * *** ** ** *** *** ** *** *** *** *** ** * *** ** *** *** *** ** * ** *** *** *** * * * ** * ** * * ** * ** * *** * *** * * *** ** *** * ** ** *** * *** *** *** *** ** * * * ** * ** ** * * ** * *** * * *** ** * *** ** ** ** *** *** ** *** ** *** *** * ** ** * ** *** *** *** *** *** *** *** *** *** ** *** *** *** *** *** ** *** *** ** ** *** *** ** *** * ** ** *** *** ** *** ** *** ** ** ** *** ** *** *** ** ** *** *** *** *** ** *** *** *** *** *** *** *** *** *** *** *** *** *** *** * * * ** ** *** ** *** *** *** *** ** *** * ** *** *** *** *** *** *** *** ** *** *** *** *** *** *** *** ** ** *** *** ** *** *** *** *** ** *** ** *** *** *** * ** ** *** *** *** * ** * *** ** *** * ** * ** * * *** ** *** * * * *** ** * *** * ** *** *** *** ** *** *** *** * * * *** * *** ** *** ** *** *** *** * * * *** ** *** *** *** *** *** *** ** *** * * * *** * *** ** *** *** *** * *** ** ** *** *** *** * * * * * ** * * ** *** *** *** *** *** *** *** *** *** * ** ** 
These two biological observations, while interesting, do not appear to be "Examples of differentiating humoral responses features identified by classification models" as the Figure 3 title states. Rather they are examples of observations possible with the high-dimensional data, which confirm or support previous observations / hypotheses. That is fine and still important -however, the authors should reframe these findings accordingly, or better highlight how the models point to these observations.
We hope that the expanded description of how these selected differences relate to classification models, as described above, provides suitable justification for the Figure 3 title.
A number of figure axes labels are illegible ( Figure S2C, S3D) . The figure 6 legend should note that the plots are shown with labeled variables in Figure S3 .
We apologize for the label sizes on supplemental figures at print size. To address this and related comments, and given potential interest in and utility of the data underlying these graphs, we have now included tables reporting the feature labels and coefficient weights for all models in the supplemental data.
We have also now added a note to the Figure 6 legend that Appendix Figure S6 (as renumbered from S3 in revision), as well as the model output tables, report the full text labels for the features used in these models.
As a more general point, the manuscript should do a better job of emphasizing that the tested variables are CORRELATED with viral control / titer, but are not necessarily causal. For instance, it is possible that the immune signatures reflect reduced viremia rather than cause it.
In the revised manuscript, we have emphasized that our findings are associative and that causality cannot be determined from this study.
See for example: Page 4: "…suggesting the value of comprehensive IgG Fab, Fc, and functional profiling to inform the identification of humoral mechanisms of action and associative relationships to viral suppression."
Page 4: "By modeling their interactions to define the underlying principles by which antibodies collaborate and/or compete to direct the overall antiviral activity of the humoral response, we define new biomarkers associated with antiviral antibody effector function, aviremia, and non-progression."
Page 6: "Whether this glycosylation state difference associated with viral load may be a cause or effect of viremic status remains to be determined, …" Page 10: "Thus, while observations using this approach are necessarily only associative, an integrated Fc-functional and deep biophysical profiling offers a unique opportunity for the identification and development of strategies that may enhance monoclonal therapeutics broadly."
Page 10: "Moreover, though this study was designed only to assess associations, …" As requested, the revised manuscript includes supplemental files that include 1) the raw experimental data (dataset EV1), 2) model outputs (dataset EV2), and 3) the code used to generate the results reported (modeling scripts EV3). We agree that such networks can be a useful visualization but can represent only a snapshot of the relationships between parameters. We provide below some sensitivity analysis below, have added more significance information to the figure, and have amended the text to better call attention to the limitations inherent to use of this type of analysis that the reviewer has noted as follows:
Finally (and crucially), the authors do not provide adequate data and analysis code. This paper is ultimately a computational analysis of large datasets
See page 7: "Balancing the competing desires of discovery and confidence, plots depicting relationships between glycoforms and Fc Array measurements with correlation coefficients exceeding an absolute value magnitude of 0.4 and an uncorrected p-value of 0.01, representing the top 7% of correlations in strength and significance, were generated." We agree that many of the antibody characteristic variables are highly correlated (as is expected given that most antibody types can interact well with most Fc receptors), and that correlated variables can adversely impact model performance. In a previous study we reported an exploration of several different dimensionality reduction approaches, and several different modeling approaches, and found that neither had a strong impact on models of antibody activity performance-wise (Choi et al, PLoS Comp Bio 2015 -http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004185).
Here, to investigate the sensitivity of the Elastic Net approach to collinearity among feaures, we evaluated alpha setting of 1.0 and 0.4, ranging from lasso-like to ridge-like, respectively, and flanking the setting of alpha = 0.8 selected for models presented in the manuscript. We find that model performance was not highly sensitive to this parameter (Response to Review Beyond these technical considerations, as the reviewer suggests, development of a minimal (and nonredundant) feature set that could encapsulate the breadth of antibody function is of high interest given the multiple antibody functions that have correlated with vaccine-mediated protection in non-human primate models across multiple vaccine approaches and regimens. As the reviewer suggests, we agree that analysis of multiple data sets, particularly those from vaccine studies (as opposed to the natural infection cohort evaluated here) would be important in order to have high confidence in the value of a reduced feature set for this purpose. Our study relates only these HIV infected subject populations, including rare controllers, highlighting key features of antibodies that may enhance their activity; we now mention that future studies aimed at further exploring the unique antibody features/profiles in in other cohorts would be of high interest.
See page 9: "However, while novel platform technologies, such as the recently described Systems Serology approach (Ackerman et al, 2017) can provide a comprehensive glimpse at the broad view of the landscape of functional responses of pathogen-specific antibodies, approaches to specifically define minimal physical biomarkers, which can be tailored to maximize information and reduce experimental redundancy, which are more easily interrogated in validated assays, and that are associated with desirable clinical outcomes, need to be further implemented to better define crosscohort, cross-regimen, and cross-pathogen principles of protective humoral immunity. We agree that MSE is a standard metric for prediction accuracy. However, we sought to explicitly compare the modeling results with experimental replicates, for which correlation coefficients are more typically reported. We also desired to enable comparisons between functional assays, whereas interpretation of MSEs across functions is complicated by the different activity ranges and magnitudes for each assay. Given this intention, we have retained the original y-axis label in Figure 5 , and note that MSE values (+/-SD over cross-validation replicates and folds) are provided for each model in Figures  S1, S2 , S3, and S4. Because these figures include MSE over varying values of lambda, they also provide useful information regarding interpretation of the MSE magnitudes.
As requested, r 2 values are now reported (Figures 5b, S3 , and S4). Figure 5 . We apologize for the confusion regarding our description. Consistent with the figure labeling, correlations between biological replicates are shown. Given the confusion this comparison and its description raised, we have tempered our description/statement as follows:
Use of biological replicates in
See page 7: "Prediction accuracy, the correlation between modeled and observed activity, was generally as good as the degree of correlation observed between assay replicates, which provides a reasonable benchmark for how well a model might be expected to perform."
Minor comments:
Figure 4: The legend in this figure should say |r|>0.4 and not r>|.4|.
We apologize for this embarrassing error. It has been corrected.
Code and data availability: Given the importance of the computational analyses performed, it would be great to share the data and code for full reproducibility.
As requested, the revised manuscript includes supplemental files that include 1) the raw experimental data (dataset EV1), 2) model outputs (dataset EV2), and 3) the code used to generate the results reported (modeling scripts EV3). 
